# US 2015/0104438 A1 · Methods of treating cancer using angiogenin or an angiogenin agonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104438 A1
- Document ID: US20150104438A1
- Status: Published application
- Kind: A1
- Application number: 14/399,852
- Filed: 2013-05-10
- Published: 2015-04-16
- Earliest claimed: 2012-05-10
- Assignees: Murray Goulburn Co-Operative Co., Limited; Agriculture Victoria Services PTY LTD
- Applicants: Murray Goulburn Co-Operative Co., Limited; Agriculture Victoria Services Pty Ltd.
- Inventors: Peter Hobman; Andrew Brown
- Web page: https://patentgrep.com/patent/US20150104438A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/515: Angiogenesic factors; Angiogenin
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12Y 301/27: Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.

## Claims

### Claim 1

A method of inducing an anti-tumour effect in a subject comprising administering to the subject an effective amount of angiogenin.

### Claim 2 (depends on 1)

The method of claim 1 in which the anti-tumour effect comprises reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival.

### Claim 3 (depends on 1)

The method of claim 1 in which angiogenin is provided as a milk extract enriched for angiogenin, optionally by cation exchange.

### Claim 4 (depends on 1)

The method of claim 1 further comprising administering to the subject of a chemotherapeutic agent, radiotherapy or both.

### Claim 5 (depends on 4)

The method of claim 4 further comprising administering to the subject a chemoprotective agent.

### Claim 6 (depends on 1)

The method of claim 1 in which the angiogenin is administered orally.

### Claim 7 (depends on 1)

The method of claim 1 in which the angiogenin is administered in a nutraceutical.

### Claim 8

A composition comprising angiogenin and a chemotherapeutic agent.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

A method of inducing an anti-tumour effect in a subject comprising administering to the subject an effective amount of the composition of claim 8.

### Claim 11 (depends on 10)

The method of claim 10 in which the anti-tumour effect comprises reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival.

### Claim 12 (depends on 10)

The method of claim 10 in which angiogenin is provided as a milk extract enriched for angiogenin, optionally by cation exchange.

### Claim 13 (depends on 10)

The method of claim 10 further comprising administering to the subject radiotherapy.

### Claim 14 (depends on 10)

The method of claim 10 further comprising administering to the subject a chemoprotective agent.

### Claim 15 (depends on 10)

The method of claim 10 in which the angiogenin is administered orally.

### Claim 16 (depends on 10)

The method of claim 10 in which the angiogenin is administered in a nutraceutical.
